Cited by 402Advanced Breast Cancer TherapiesCancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 285 of the 292 references it cites were found in a registry or an index.

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Open access

Whittaker, Steven R., Mallinger, Aurélie, Workman, Paul, Clarke, Paul A.·2017·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2017.02.008PMC PMC6141011

Open this paper in CoChat — free account

Abstract

Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs). This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer. CDKs have now been shown to regulate other processes, particularly various aspects of transcription. The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers. The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors. However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest. Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER+/HER2- advanced breast cancer. Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compounds that have allowed exploration of individual CDKs as cancer targets and the determination of their potential therapeutic windows. Biomarkers that allow the selection of patients likely to respond are now being discovered. Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors. This suggests that the selective inhibitors may be best used combined with standard of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2017.02.008

Cites

285 of 285 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Cancer Cell Cycles
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Héry-Arnaud, G., Berre, R. L., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 5,008
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 1×
“In any case, RB remains phosphorylated throughout the S, G2 and M phases, and at the end of mitosis it is dephosphorylated by protein phosphatase 1 (Malumbres & Barbacid, 2009).”
The Role of Chromatin during Transcription
Li, B., Carey, M., & Workman, J. L. (2007) · Cell · doi:10.1016/j.cell.2007.01.015 · Cited by 3,503
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900

Show all 292 references

Sorted by citations

Items 301–400 of 402

Palladium-catalyzed Suzuki–Miyaura and Buchwald–Hartwig cross-coupling reactions towards the synthesis of pharmacologically potent pyrimidine-based molecules
Aman, F., Aman, L., Rasool, N., Arshad, M., Imran, M., Malik, A. I., & Iqbal, S. (2026) · Molecular Diversity · doi:10.1007/s11030-025-11459-1 · Cited by 2
Exploring imidazo[1,2-a]pyridine hybrids in cancer therapy: ADMET profiling, molecular docking, MD simulations and DFT calculations
Shah, D., Nagani, A., Shah, M., & Patel, A. (2026) · Scientific Reports · doi:10.1038/s41598-026-39575-4 · Cited by 2
Three compounds from banana pseudostem inhibit mitotic cell division by interacting with tubulin and cyclin-dependent kinase 2 proteins: in vivo, in vitro and in silico approach
Rajesh, C., Sahoo, S., Balaji, S. K., Prakash, R., Selvapalam, N., & Palanichelvam, K. (2023) · Journal of Plant Biochemistry and Biotechnology · doi:10.1007/s13562-023-00861-1 · Cited by 2
Ibulocydine Inhibits Migration and Invasion of TNBC Cells via MMP-9 Regulation
Kwon, M. R., Park, J. S., Ko, E. J., Park, J. H., Ju, E., Shin, S.-H., Son, G. W., Lee, H. W., Park, Y., Park, Y.-Y., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116123 · Cited by 2
Phytochemicals as a complementary alternative medicine in cancer treatment
Das, K., Dhanalakshmi, M., Pandya, M. D., Sruthi, D., & Dave, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-19143-5.00006-2 · Cited by 2
Methods to study xenografted human cancer in genetically diverse micePreprint
Hasham, M. G., Sargent, J. K., Warner, M. A. A., Farley, S. R., Hoffmann, B. R., Stodola, T. J., Brunton, C., & Munger, S. C. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.23.576906 · Cited by 2
Exploration of Potential Cyclin-dependent Kinases and their Inhibitors to Combat Abnormal Signalling and Cancer
Pilania, P., Nandi, S., Meena, D. K., & Sharma, B. K. (2024) · Current Signal Transduction Therapy · doi:10.2174/0115743624279638240211170045 · Cited by 1
Elucidating the Mechanisms of Acquired Palbociclib Resistance via Comprehensive Metabolomics Profiling
Yang, L., Yue, Y., Wang, Z., Jiang, Y., Xue, Z., & Zhang, Y. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47010024 · Cited by 1
Discovery of a new hydrazone-oxamide hybrid capable of inducing necroptotic cell death in triple negative breast cancer cells
Akhavan, R., Harsini, S. J., Shafiee, S., Eftekhari, M., Tahmasvand, R., Taghipour, F., Kooshafar, Z., Mohammadmirzaeizarandi, H., Salimi, M., Almasirad, A., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108267 · Cited by 1
Investigation of Novel Cyclin‐Dependent Kinase 4 Inhibitors for Cancer Treatment: In Silico Approach Using Natural Product Libraries
Bhambri, S., & Jha, P. C. (2025) · Advanced Theory and Simulations · doi:10.1002/adts.202401412 · Cited by 1
CRISPR-Cas9 Genome and Double-Knockout Screening to Identify Novel Therapeutic Targets for Chemoresistance in Triple-Negative Breast Cancer
Shao, S., Li, S., Huo, Y., Tang, S., Gökbağ, B., Fan, K., Huang, Y., Wang, L., Nagy, G., Parvin, J. D., et al. (2025) · Cancers · doi:10.3390/cancers17233876 · Cited by 4
CDK9 and hematologic malignancies: pioneering novel therapeutic approaches
Raufi, H., Zahmatkesh, P., Safaei, S., Bahadori, A., & Solali, S. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02141-3 · Cited by 1
Utilizing Molecular Dynamics and Mechanistic Pharmacokinetic Studies in the Design of Selective CDK2 Inhibitors
Verma, V. A., Grandner, J. M., Parr, B. T., Zeng, M., Ashley, M., Wang, Y., Beroza, P., Carione, P., Johnson, K. M., Oh, A. J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03803 · Cited by 1
Design and synthesis of dual-target CDK9-EZH2 inhibitors using a pharmacophore fusion strategy
Han, Y., Wang, R., Tian, L., Xiao, J., Wei, A., Ding, J., Chen, Y., Hu, Y., Fang, Y., & Li, X. (2026) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2026.130747 · Cited by 1
Molecular dynamics simulations reveal the determinants of cyclin-dependent kinase 2 inhibition by 5-nitrosopyrimidine derivatives
Guglielmo, S., Cortese, D., Cano, C., & Fruttero, R. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1666032 · Cited by 1
The Prospects of RNAs and Common Significant Pathways in Cancer Therapy and Regenerative Medicine
Gattupalli, M., Dey, P., Poovizhi, S., Patel, R. B., Mishra, D., & Banerjee, S. (2023) · Springer eBooks · doi:10.1007/978-981-19-6008-6_16 · Cited by 1
Transduction of miRNA-155 and miRNA-34a in Oral Squamous Cell Carcinoma Cell Line
(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.30.08.026 · Cited by 1
Prognostic Significance of P21 Protein in Breast Cancer
Jovanović, D., Mitrović, S., Alić, D., Besic, D., Knezevic, D., Dimitrijević, J., & Ilić, M. (2023) · EABR. Experimental and Applied Biomedical Research · doi:10.2478/sjecr-2023-0005 · Cited by 1
In-silico design, synthesis and biological evaluation of 4-aryl-4H-chromene derivatives as CDK-2 inhibitors: A molecular approach to finding a lead for breast cancer
Amin, S., Patil, P. H., Desai, M. P., & Channabasavaiah, J. P. (2024) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2024.155052 · Cited by 1
Molecular modeling in synthesis: from statistical methods to quantum chemistry and practical applications
Svitanko, I. V., & Pivina, T. S. (2024) · Russian Chemical Bulletin · doi:10.1007/s11172-024-4226-6 · Cited by 1
Studying Cellular Senescence Using the Model Organism Drosophila melanogaster
Louka, X. P., Gumeni, S., & Trougakos, I. P. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4426-3_17 · Cited by 2
Application of RNA-sequencing to identify transcriptome modification by DCLK1 in colorectal cancer cells
Li, L., Mei, H., & Commey, A. N. A. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-019-0144-4 · Cited by 1
CYCLIN D1: As a Risk of Breast Cancer
Chauhan, P., Kaur, P. S., & Babu, A. M. (2020) · CGC International Journal of Contemporary Technology and Research · doi:10.46860/cgcijctr.2020.12.26.134 · Cited by 1
Identifying Novel Therapeutic Targets for Overcoming TNBC Chemo Resistance Through Comprehensive CRISPR-Cas9 Genome ScreeningPreprint
Shao, S., Li, S., Tang, S., Fan, K., & Li, L. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.14.594192 · Cited by 1
Obtenção e caracterização estrutural da proteína humana Quinase Dependente de Ciclina 9 (CDK9) utilizando o sistema bacteriano de Escherichia coli
Alencar, D. P. (2019) · doi:10.11606/d.75.2019.tde-15102019-155920
Tumor-specific genetic profiling and therapy in biomedicine
Uzuner, E., Kiraz, Y., & Baran, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819541-3.00023-2
Overexpression and refolding of human Cyclin D3. A reliable method or not?
Coelho, F., Pepino, R. D. O., Alencar, D. P., Santos, J. L., & Canduri, F. (2020) · Process Biochemistry · doi:10.1016/j.procbio.2020.09.004
Development of molecular inhibitor nanoformulations for cancer therapy
Baldwin, P. (2019) · Digital Repository Service (Northeastern University) · doi:10.17760/d20317945
Investigating the Role of CDK11 in Animal Cytokinesis
Panagiotou, T. C. (2020) · TSpace (University of Toronto)
Novel probes, carriers and prodrugs to target senescent cells in vivo
Lozano‐Torres, B. (2021) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/172175
Clonagem, expressão, purificação e caracterização biofísica da proteína quinase dependente de ciclina 11 obtida pela expressão em Escherichia coli
Pepino, R. D. O. (2021) · doi:10.11606/t.75.2021.tde-25112021-092117
Faculty Opinions recommendation of Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.
Tolar, J., & Thompson, E. A. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736585207.793566947
Faculty Opinions recommendation of Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.
Khachigian, L. M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736585207.793565997
Faculty Opinions recommendation of Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.
Anderson, K. S. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736585207.793570659
Faculty Opinions recommendation of Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.
Zhang, W., & Porterfield, W. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736585207.793569236
The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response
Barone, G., Arora, A., Ganesh, A., Abdel-fatah, T., Moseley, P., Ali, R., Chan, S. Y. T., Savva, C., Schiavone, K., Carmell, N., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.v9i50
Faculty Opinions recommendation of Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.
Walczak, C. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736585207.793567427
Cell Cycle Arrest Biomarkers in the Intensive Care Unit
Zhou, Z., & Yang, B. (2022) · Biomarkers in disease · doi:10.1007/978-3-030-87302-8_10-1
Preclinical evaluation of senescence-based strategies to improve cancer therapy
Estepa‐Fernández, A. (2022) · RiuNet (Universitat Politècnica de València) · doi:10.4995/thesis/10251/188845
Clonagem, expressão, purificação e caracterização da proteína ciclina D3 obtida pela expressão em sistema bacteriano (Escherichia coli)
Coelho, F. (2022) · doi:10.11606/t.75.2022.tde-17112022-110011
Cell cycle
Mahesh, A. N., Bhatia, K. S., & Bhatt, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00256-6
La proteína MAD2 como posible biomarcador diagnóstico en cáncer
Alcázar, D. G. (2021) · doi:10.24275/uami.v979v329b
Association between mutant E6 and E7 Human Papilloma Virus Type 16 oncogenes with cyclin D1 expression in cervical cancer: Observational study in Bali
Mahendra, I. N. B., Budiana, I. N. G., Putra, I. G. M., Suardika, A., Wiradnyana, A. A. G. P., & Sari, A. N. (2023) · F1000Research · doi:10.12688/f1000research.128537.1
Pten is a disconnecting node in the molecular landscape of the proliferation/quiescence decision during mammary gland acinogenesisPreprint
Tomasin, R., Rodrigues, A. M., Manucci, A. C., & Bruni‐Cardoso, A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.13.532403
Cell Cycle Arrest Biomarkers in the Intensive Care Unit
Zhou, Z., & Yang, B. (2023) · Biomarkers in disease · doi:10.1007/978-3-031-07395-3_10
Cellular selectivity and kinetics of clinical kinase inhibitors
Berger, L. M. (2023) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.72279
Distinct states of nucleolar stress induced by anti-cancer drugsPreprint
Potapova, T., Unruh, J. R., Conkright-Fincham, J., Banks, C. A. S., Florens, L. A., Schneider, D. A., & Gerton, J. L. (2023) · eLife · doi:10.7554/elife.88799.2
Racial Disparities in the Genetic Landscape of Acute Myeloid Leukaemia from The Cancer Genome Atlas: Insights from a Bioinformatics AnalysisPreprint
Nkhoma, P., Dzobo, K., Kafita, D., Kwenda, G., Munsaka, S. M., & Sinkala, M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.06.565754
Immunohistochemical Study of Cyclin Dependant Kinase5 (CDK5) in Some Hyperproliferative Skin Disorders
El‐Taweel, A. E. I., Mohamed, H., Elesawy, F. M., Akl, E. M., & El-Aziz, N. A. (2023) · Benha Journal of Applied Sciences · doi:10.21608/bjas.2023.241988.1268
Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin- dependent kinases (CDKs)Preprint
Wesselborg, S., Schmitt, L., Hoppe, J., Cea‐Medina, P., Bruch, P., Krings, K. S., Hinxlage, I., Drießen, D., Peter, C., Bhatia, S., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3857577/v1
The hsa-miR-1246 is overexpressed in Spheroids-derived cancer stem cells from tumor cell linesPreprint
Fonseca, Á. G., González‐Giraldo, Y., Vargas-Rondón, N., & Aristizábal-Pachón, A. F. (2025) · Research Square · doi:10.21203/rs.3.rs-6222076/v1
Transcriptome analysis reveals the candidate genes associated with skin color variation in Luciobarbus capito
Geng, L., Shang, X., Wei, H., Tong, G., Xu, W., & Kuang, Y. (2025) · Aquaculture Reports · doi:10.1016/j.aqrep.2025.102969
A Review of Recent Developments in Schiff Base Derivatives for Cancer Treatment
Ngu, C. P., Sahu, R., Shah, K., Paliwal, D., Sah, A. K., & Thakur, A. (2025) · Current Organic Chemistry · doi:10.2174/0113852728405259250924102913
Design, synthesis and molecular docking of Pyrazolo[3,4-b]pyridine derivatives as potential CDK2 pathway inhibitors in colorectal cancer cells
Issa, D. A. E., Kassem, Z. A., Staiteieh, S. A., Youssef, A., Nasr, J., Darwiche, N., & Merhi, R. A. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109335
Additional file 1 of Upregulation of miR-1825 inhibits the progression of glioblastoma by suppressing CDK14 though Wnt/β-catenin signaling pathway
Lu, F., Li, C., Sun, Y., Jia, T., Li, N., & Li, H. (2020) · Figshare · doi:10.6084/m9.figshare.12592890
Additional file 1 of Combination strategies to overcome drug resistance in FLT+ acute myeloid leukaemia
Yang, J., & Friedman, R. (2024) · Figshare · doi:10.6084/m9.figshare.26609790
Degradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy
Tian, X., Dai, X., Zhong, Y., Cheng, M., & Liu, Y. (2025) · Pharmaceutical Fronts · doi:10.1055/a-2742-7859
Harnessing mechanobiology for hair regeneration: emerging techniques and therapies
Bhattacharya, B., Das, A., & Roy, S. (2025) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/ae30ba
Design, Synthesis, and Preclinical Evaluation of Inhibitor-Based Radiotracers for Potential Application in Monitoring CDK4/6 Expression
Pan, Y. J., Zhang, X. M., Zhou, B., Ma, Y., Hu, J., He, J., Shang, X., Zhang, C., Liang, T. B., & Gao, F. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03163
Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial
Rubio‐San‐Simón, A., Marshall, L. V., Karamouza, E., André, N., Abbou, S. D., Rubino, J., Nebchi, S., Aerts, I., Thébaud, E., Brisset, C., et al. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01208-1
hsa-miR-1246 is Consistently Overexpressed in Spheroid-Derived Cancer Stem Cells From Multiple Tumor Types
Fonseca, Á. Y. G., González‐Giraldo, Y., Vargas-Rondón, N., & Aristizábal-Pachón, A. F. (2026) · Cancer Informatics · doi:10.1177/11769351251414086
Considerations for establishing occupational exposure limits for small molecule kinase inhibitors in drug development
Nicholas, T. P., Morinello, E. J., Moudgal, C. J., Beaulieu, A., & Graham, J. C. (2026) · Frontiers in Toxicology · doi:10.3389/ftox.2026.1743558
sp²-Iminosugar-glucosidases inhibitor 1-C-octyl-2-oxa-3-oxocastanospermine - induced antiproliferative, apoptotic and necrotic effects in breast cancer cells via targeting GRP78, Stim1 and Orai1
Gueder, N. (2018) · theses.fr (ABES) · doi:10.70675/8c00a7dcz3839z4c4ezb4e9z9258da4b4da5
Calcium signature in the pancreatic cancer : role in the activation of the pancreatic stellate cells and in the progression of the pancreatic cancer
Radoslavova, S. (2021) · theses.fr (ABES) · doi:10.70675/caff0fc7z69abz4a91z9ffez4ae67a4969ae
Inhibition of CDK9 sensitizes multidrug resistant ovarian cancer cells to paclitaxel
Wang, J., Hornicek, F. J., Shi, H., Feng, W., & Duan, Z. (2026) · Scientific Reports · doi:10.1038/s41598-026-47843-6
Rôle des vésicules extracellulaires endothéliales dans la propagation de signaux pro-sénescents et thrombo-inflammation
Saraswat, R. (2023) · theses.fr (ABES) · doi:10.70675/3d5bf12az3e72z4677za3a5z78e1cff69297
Targeted protein degradation in the digital era: Computational challenges and opportunities for PROTACs
Tewari, A., Pawar, A. B., & Roy, S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100372 · Cited by 1
Design, synthesis, anticancer estimation, and computational studies of novel benzochromenoimidazopyrimidines as CDK-2 inhibitors and apoptosis stimulators
Abdulrahman, F. G., Sarg, M. T. M., Sheta, Y. S., Nossier, E. S., & Husseiny, E. M. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11578-3
Overview of Pyrazolo[1,5‐ a ]Pyrimidines Scaffold: Synthetic Strategies, Drug Synthesis, Structure–Activity Relationships, and Their Functional Fluorophores
Embaby, D., El-Rashedy, A. A. E., Hammad, S. F., & Elshaier, Y. A. M. M. (2026) · ChemistrySelect · doi:10.1002/slct.202506991
In silico study of potent polyphenolic phytochemicals as natural inhibitors against kinase enzymes in breast and lung cancer
Majumdar, S., Sahu, P. N., Pramanik, A., & Sen, A. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100499
The Role of Cellular Senescence in Chronic Lung Diseases: Emerging Mechanisms and Translational Perspectives: A Narrative Review
Etrouth, S., Zhu, Y., & Zhang, D. (2026) · Journal of Respiration · doi:10.3390/jor6030021
A framework for prioritizing novel agents in malignant peripheral nerve sheath tumor trials: A report from the neurofibromatosis clinical trials consortium
Zhang, L., Eulo, V. A., Akshintala, S., Armstrong, A. E., Gross, A. M., Klesse, L. J., Lemberg, K. M., Monga, V., Sait, S. F., Fisher, M. J., et al. (2026) · Neuro-Oncology · doi:10.1093/neuonc/noag192
Molecular targeting of CDK9 in oncology therapeutics: avenues for translational impact
Liu, T., Liu, Z., Wei, W., Wang, S., Wang, S., Zhang, Y., Gao, Z., & Wu, W. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2723483
Inhibition of cyclin-dependent kinase 8 modulates chondrocyte transition to hypertrophy and provides in vivo protection against spontaneous osteoarthritis
Wells, L. M., Keen, J. A. C., Sharma, A., Marr, N., Hansen, R., Pereira, J. S., Roe, T., Roberts, L. D., Oppermann, U. C. T., Clarke, P. A., et al. (2026) · Bone Research · doi:10.1038/s41413-026-00551-3
Self-citation
Gallic acid enhances radiosensitivity in pancreatic ductal adenocarcinoma models in association with CRL4-DCAF1-related CDK1 destabilization and ROS-associated DNA damage amplification
Yang, C., Feng, S., Wang, J., Xue, Z., Zhao, J., Xu, J., & Zou, L. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158813
BindingDB Entry 50021723: Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors.
BindingDB (2025) · UC San Diego · doi:10.7270/q2251pvt
BindingDB Entry 50018815: Design, synthesis and anticancer evaluation of selective 2,4-disubstituted pyrimidine CDK9 inhibitors.
BindingDB (2024) · UC San Diego · doi:10.7270/q2g73k0j
BindingDB Entry 50007709: Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
BindingDB (2021) · UC San Diego · doi:10.7270/q26q21j2
BindingDB Entry 50016886: Discovery of 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and selective CDK9 inhibitors that enable transient target engagement for the treatment of hematologic malignancies.
BindingDB (2023) · UC San Diego · doi:10.7270/q2154n2x
BindingDB Entry 50001876: Discovery of the selective and efficacious inhibitors of FLT3 mutations.
BindingDB (2020) · UC San Diego · doi:10.7270/q2668gsp
BindingDB Entry 50010555: Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.
BindingDB (2021) · UC San Diego · doi:10.7270/q2c53qdz
BindingDB Entry 50021509: Discovery and optimization of thieno[3,2-d]pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7.
BindingDB (2025) · UC San Diego · doi:10.7270/q2x92gxr
BindingDB Entry 50010508: CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?
BindingDB (2021) · UC San Diego · doi:10.7270/q2c82dt8
BindingDB Entry 50018341: A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.
BindingDB (2024) · UC San Diego · doi:10.7270/q2pk0mc2
BindingDB Entry 50012265: Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry.
BindingDB (2022) · UC San Diego · doi:10.7270/q29w0k46
BindingDB Entry 50018557: Discovery of Novel
BindingDB (2024) · UC San Diego · doi:10.7270/q29k4ggv
BindingDB Entry 50016036: Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
BindingDB (2023) · UC San Diego · doi:10.7270/q2kk9gtq
BindingDB Entry 50012045: Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
BindingDB (2022) · UC San Diego · doi:10.7270/q2fb56k3
BindingDB Entry 50022443: Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer.
BindingDB (2025) · UC San Diego · doi:10.7270/q2d50spj
BindingDB Entry 50023733: Discovery of potent and selective CDK2 inhibitors with high safety and favorable bioavailability for the treatment of cancer.
BindingDB (2026) · UC San Diego · doi:10.7270/q29z99vd
BindingDB Entry 50023566: Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): Emerging strategies for cancer therapy.
BindingDB (2026) · UC San Diego · doi:10.7270/q2vq37mq
BindingDB Entry 50001991: Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors.
BindingDB (2020) · UC San Diego · doi:10.7270/q2h134k1
BindingDB Entry 50008712: 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
BindingDB (2021) · UC San Diego · doi:10.7270/q2g1647c
BindingDB Entry 50007244: Discovery of a highly selective FLT3 inhibitor with specific proliferation inhibition against AML cells harboring FLT3-ITD mutation.
BindingDB (2021) · UC San Diego · doi:10.7270/q2s185r2
BindingDB Entry 50016051: Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
BindingDB (2023) · UC San Diego · doi:10.7270/q2xw4ps2
BindingDB Entry 50008182: Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent in vitro and in vivo antitumor activity.
BindingDB (2021) · UC San Diego · doi:10.7270/q2xp789w
BindingDB Entry 50014244: Discovery of
BindingDB (2022) · UC San Diego · doi:10.7270/q2zg6x2g
BindingDB Entry 50021779: Discovery of novel macrocyclic derivatives as potent and selective cyclin-dependent kinase 2 inhibitors.
BindingDB (2025) · UC San Diego · doi:10.7270/q2ks6x6z
BindingDB Entry 50013297: Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer.
BindingDB (2022) · UC San Diego · doi:10.7270/q2tm7fvh
BindingDB Entry 50023057: Structure-Guided Discovery of Novel N4-(Substituted Thiazol-2-yl)-N2-(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability.
BindingDB (2026) · UC San Diego · doi:10.7270/q2zw1rs2

Authors: Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A.
Affiliations: Institute of Cancer Research (GB)
Corresponding author: Clarke, Paul A.
ORCID: Whittaker, Steven R.
Workman, Paul
Clarke, Paul A.
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2017-05
Volume: 173
Pages: 83-105
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2017.02.008
PMC: PMC6141011
OpenAlex: W2583136106
Cited by: 384
References: 292
Citations by year: 2026: 25 · 2025: 38 · 2024: 37 · 2023: 47 · 2022: 38 · 2021: 53 · 2020: 55 · 2019: 51 · 2018: 25 · 2017: 15
FWCI: 7.38
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Cancer Research UK (C309/A11566, C368/A6743, A368/A7990)
Topics: Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: cyclin-dependent kinases, cyclin-dependent kinase inhibitors, isoform-selective inhibitors, CDK4/6 inhibitors, palbociclib, breast cancer, cell cycle regulation, tumor cell proliferation, biomarkers, drug resistance, combination therapy, protein kinase inhibitors
MeSH terms: Animals, Antineoplastic Agents, Cell Cycle, Humans, Neoplasms, Drug Design, Cyclin-Dependent Kinases, Protein Kinase Inhibitors, Cell Proliferation, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibitors of cyclin-dependent kinases as cancer therapeutics.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks